Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Argenx SE, CSL Limited, GeNeuro SA, Immupharma Plc, Momenta Pharmaceuticals Inc and others.
A Significant contribution to the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline included 11 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) condition and increased access to investments is encouraging growth of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Further, orphan drug status, fast track designation, grants awarded and other special status for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline candidates-
A Significant contribution to the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline included 11 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) condition and increased access to investments is encouraging growth of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Further, orphan drug status, fast track designation, grants awarded and other special status for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) drugs
- Late phase: Phase 3 and in-approval Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) drugs
- Company overview
- Snapshot
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Disease Overview
2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Pipeline Snapshot
2.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Pipeline Drugs by Phase
2.4 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Pipeline Drugs by Company
2.5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Argenx SE Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.2 CSL Limited Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.3 GeNeuro SA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.4 Immupharma Plc Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.5 Momenta Pharmaceuticals Inc Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.6 Octapharma AG Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.7 Pfizer Inc Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.8 Takeda Pharmaceutical Co Ltd Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.9 Teijin Pharma Ltd Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.10 UCB Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.11 Zenyaku Kogyo Co Ltd Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Phase 1 Drug Details
4.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Phase 1 Drug Overview
4.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Phase 2 Drug Details
5.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Phase 2 Drug Overview
5.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Phase 3 Drug Details
6.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Phase 3 Drug Overview
6.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Pre-clinical Phase Drug Details
7.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Pre-clinical Phase Drug Overview
7.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Disease Overview
2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Pipeline Snapshot
2.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Pipeline Drugs by Phase
2.4 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Pipeline Drugs by Company
2.5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Argenx SE Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.2 CSL Limited Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.3 GeNeuro SA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.4 Immupharma Plc Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.5 Momenta Pharmaceuticals Inc Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.6 Octapharma AG Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.7 Pfizer Inc Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.8 Takeda Pharmaceutical Co Ltd Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.9 Teijin Pharma Ltd Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.10 UCB Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
3.11 Zenyaku Kogyo Co Ltd Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Phase 1 Drug Details
4.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Phase 1 Drug Overview
4.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Phase 2 Drug Details
5.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Phase 2 Drug Overview
5.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Phase 3 Drug Details
6.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Phase 3 Drug Overview
6.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Pre-clinical Phase Drug Details
7.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Pre-clinical Phase Drug Overview
7.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
